Free tool
FAERS Monitor: Cosentyx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125504 or its brand name (Cosentyx, Secukinumab). Reports on generic versions are filed under their own applications.
Reports
161,904
Serious
65,379
40% of reports
Hospitalization
22,508
Death reported
9,022
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective29,381
- psoriasis22,918
- pain16,854
- arthralgia15,102
- fatigue10,786
- psoriatic arthropathy10,387
- malaise9,598
- pruritus9,542
- rash9,297
- condition aggravated8,697
- diarrhoea8,168
- nasopharyngitis7,955
- headache7,440
- pain in extremity7,432
- off label use7,053
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 11 |
| 2015 | 2,812 |
| 2016 | 6,260 |
| 2017 | 11,695 |
| 2018 | 20,874 |
| 2019 | 21,465 |
| 2020 | 22,595 |
| 2021 | 17,026 |
| 2022 | 17,155 |
| 2023 | 17,264 |
| 2024 | 11,057 |
| 2025 | 9,204 |
| 2026 | 4,482 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,892,255 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriatic arthropathySignal | 10,387 | 44.3 | 43.4 | 327,970 |
| psoriasisSignal | 22,918 | 27.4 | 27.1 | 484,286 |
| nasopharyngitisSignal | 7,955 | 5.8 | 5.7 | 30,603 |
| arthralgiaSignal | 15,102 | 4.9 | 4.8 | 45,494 |
| condition aggravatedSignal | 8,697 | 3.8 | 3.7 | 17,652 |
| painSignal | 16,854 | 3.6 | 3.6 | 32,275 |
| pain in extremitySignal | 7,432 | 3.3 | 3.3 | 12,014 |
| pruritusSignal | 9,542 | 3.3 | 3.2 | 15,039 |
| drug ineffectiveSignal | 29,381 | 2.9 | 2.9 | 39,212 |
| malaiseSignal | 9,598 | 2.9 | 2.8 | 11,800 |
| rashSignal | 9,297 | 2.8 | 2.8 | 10,825 |
| fatigue | 10,786 | 1.8 | 1.8 | 4,011 |
| diarrhoea | 8,168 | 1.7 | 1.6 | 2,141 |
| headache | 7,440 | 1.5 | 1.5 | 1,470 |
| off label use | 7,053 | 1.0 | 1.0 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.